File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/S0954-6111(89)80200-8
- Scopus: eid_2-s2.0-0024434962
- PMID: 2692094
- WOS: WOS:A1989AP01800008
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Ofloxacin compared with amoxycillin in treating infective exacerbations in bronchiectasis
Title | Ofloxacin compared with amoxycillin in treating infective exacerbations in bronchiectasis |
---|---|
Authors | |
Issue Date | 1989 |
Publisher | Elsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/rmed |
Citation | Respiratory Medicine, 1989, v. 83 n. 4, p. 299-303 How to Cite? |
Abstract | Forty-one hospitalized adult patients of bronchiectasis (non-cystic fibrosis) with infective exacerbations were entered into a randomized, double-blind, placebo-controlled study comparing ofloxacin (200 mg tid) and amoxycillin (1 g tid) both orally for ten days. In the ofloxacin group (20 patients), improvement in sputum purulence was excellent in 14, and fair in five patients with one failure. In the amoxycillin group (21 patients), improvement in sputum purulence was excellent in eight, fair in five and poor in eight patients. Mean drug levels on day 5 were 4.1 mg l -1 for serum (2 h post-dosage) and 4.0 mg l -1 for sputum for ofloxacin, and 18.4 mg l -1 for serum and 0.3 mg l -1 for sputum for amoxycillin. Ofloxacin thus yielded higher sputum concentration and appeared to be more effective and also better tolerated than amoxycillin in infective episodes of bronchiectasis. |
Persistent Identifier | http://hdl.handle.net/10722/161787 |
ISSN | 2023 Impact Factor: 3.5 2023 SCImago Journal Rankings: 1.180 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lam, WK | en_US |
dc.contributor.author | Chau, PY | en_US |
dc.contributor.author | So, SY | en_US |
dc.contributor.author | Leung, YK | en_US |
dc.contributor.author | Chan, JCK | en_US |
dc.contributor.author | Ip, M | en_US |
dc.contributor.author | Sham, MK | en_US |
dc.date.accessioned | 2012-09-05T05:14:58Z | - |
dc.date.available | 2012-09-05T05:14:58Z | - |
dc.date.issued | 1989 | en_US |
dc.identifier.citation | Respiratory Medicine, 1989, v. 83 n. 4, p. 299-303 | en_US |
dc.identifier.issn | 0954-6111 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/161787 | - |
dc.description.abstract | Forty-one hospitalized adult patients of bronchiectasis (non-cystic fibrosis) with infective exacerbations were entered into a randomized, double-blind, placebo-controlled study comparing ofloxacin (200 mg tid) and amoxycillin (1 g tid) both orally for ten days. In the ofloxacin group (20 patients), improvement in sputum purulence was excellent in 14, and fair in five patients with one failure. In the amoxycillin group (21 patients), improvement in sputum purulence was excellent in eight, fair in five and poor in eight patients. Mean drug levels on day 5 were 4.1 mg l -1 for serum (2 h post-dosage) and 4.0 mg l -1 for sputum for ofloxacin, and 18.4 mg l -1 for serum and 0.3 mg l -1 for sputum for amoxycillin. Ofloxacin thus yielded higher sputum concentration and appeared to be more effective and also better tolerated than amoxycillin in infective episodes of bronchiectasis. | en_US |
dc.language | eng | en_US |
dc.publisher | Elsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/rmed | en_US |
dc.relation.ispartof | Respiratory Medicine | en_US |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Amoxicillin - Administration & Dosage - Therapeutic Use | en_US |
dc.subject.mesh | Bacteria - Isolation & Purification | en_US |
dc.subject.mesh | Bacterial Infections - Drug Therapy - Microbiology | en_US |
dc.subject.mesh | Bronchiectasis - Drug Therapy - Microbiology | en_US |
dc.subject.mesh | Double-Blind Method | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Microbial Sensitivity Tests | en_US |
dc.subject.mesh | Ofloxacin - Administration & Dosage - Therapeutic Use | en_US |
dc.subject.mesh | Randomized Controlled Trials As Topic | en_US |
dc.subject.mesh | Sputum - Microbiology | en_US |
dc.title | Ofloxacin compared with amoxycillin in treating infective exacerbations in bronchiectasis | en_US |
dc.type | Article | en_US |
dc.identifier.email | Ip, M:msmip@hku.hk | en_US |
dc.identifier.authority | Ip, M=rp00347 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1016/S0954-6111(89)80200-8 | - |
dc.identifier.pmid | 2692094 | - |
dc.identifier.scopus | eid_2-s2.0-0024434962 | en_US |
dc.identifier.volume | 83 | en_US |
dc.identifier.issue | 4 | en_US |
dc.identifier.spage | 299 | en_US |
dc.identifier.epage | 303 | en_US |
dc.identifier.isi | WOS:A1989AP01800008 | - |
dc.publisher.place | United Kingdom | en_US |
dc.identifier.scopusauthorid | Lam, WK=7203021937 | en_US |
dc.identifier.scopusauthorid | Chau, PY=36509704300 | en_US |
dc.identifier.scopusauthorid | So, SY=7102397816 | en_US |
dc.identifier.scopusauthorid | Leung, YK=7201463867 | en_US |
dc.identifier.scopusauthorid | Chan, JCK=23090202000 | en_US |
dc.identifier.scopusauthorid | Ip, M=7102423259 | en_US |
dc.identifier.scopusauthorid | Sham, MK=7003729112 | en_US |
dc.identifier.issnl | 0954-6111 | - |